08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
In this OnPoint, we report on two changes to the taxation of termination payments to departing emplo...
Read More >
Robinson+Cole’s Construction Group is pleased to bring you a recap of posts from our Construction L...
Read More >
U.S. Citizenship and Immigration Services (USCIS) opened its initial registration period for the fis...
Read More >
Why This Matters - Last week, the California Supreme Court dealt tech giant Apple Inc. a blow when ...
Read More >
Employers sometimes include fixed terms of employment in their employment agreement. Sometimes a fix...
Read More >
Schneider Nat’l Carriers, Inc. v. Kuntz, C.A. No. 2017-0711-PAF (Del. Ch. July 16, 2020) - If part...
Read More >